Filing Details

Accession Number:
0001144204-19-045297
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-19 19:12:21
Reporting Period:
2019-09-17
Accepted Time:
2019-09-19 19:12:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1773427 Springworks Therapeutics Inc. SWTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1231954 P Stephen Squinto C/O Springworks Therapeutics, Inc.
100 Washington Blvd.
Stamford CT 06902
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-17 6,078,103 $0.00 6,078,103 No 4 C Indirect See footnote
Common Stock Acquisiton 2019-09-17 1,053,204 $0.00 7,131,307 No 4 C Indirect See footnote
Common Stock Acquisiton 2019-09-17 275,000 $18.00 7,406,307 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2019-09-17 6,078,103 $0.00 6,078,103 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2019-09-17 1,053,204 $0.00 1,053,204 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
  2. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
  3. Shares held by OrbiMed Capital GP VI LLC ("GP VI"). GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.